Ionis Pharmaceuticals, Inc. (IONS) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Carlsbad, CA, United States. Der aktuelle CEO ist Brett Monia.
IONS hat IPO-Datum 1991-05-17, 1,069 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $12.68B.
Ionis Pharmaceuticals, Inc. is a biopharmaceutical company based in Carlsbad, California, specializing in the discovery and development of RNA-targeted therapeutics. The company markets approved treatments including SPINRAZA for spinal muscular atrophy, TEGSEDI for hereditary transthyretin-mediated amyloidosis, and WAYLIVRA for familial lipid disorders, while maintaining a robust pipeline of Phase 3 candidates targeting rare genetic diseases, cardiovascular conditions, and neurological disorders. Through strategic collaborations with major pharmaceutical partners including Biogen, AstraZeneca, Bayer, GlaxoSmithKline, Novartis, and Roche, Ionis is advancing its platform across metabolic diseases, infectious diseases, renal diseases, and oncology.
